Founded in 2021, Epigenic Therapeutics is focused on utilizing regulation of epigenetic genome for treating a variety of diseases. Its EPIREG® proprietary technology platform employs its own artificial intelligence (AI) algorithms to explore and obtain innovative CRISPR-Cas components to regulate target gene(s) expression without changing the DNA sequence. Combining a patented lipid nanoparticle (LNP) delivery system, its platform has been proven to precisely and efficiently deliver medicine to targeted cells and tissues in metabolic, cardiovascular, viral hepatitis, ophthalmology, oncology and rare disease models.
